Minimally Invasive and Emerging Diagnostic Approaches in Endometrial Cancer: Epigenetic Insights and the Promise of DNA Methylation DOI Creative Commons

Floriana Porcaro,

Alessandra Paolucci,

Piercarmine Porcaro

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(22), P. 2575 - 2575

Published: Nov. 15, 2024

Endometrial cancer (EC) is the most common gynecological malignancy, with rising incidence and mortality rates. Key risk factors, including obesity, prolonged estrogen exposure, metabolic disorders, underscore urgent need for non-invasive, early diagnostic tools. This review focuses on role of DNA methylation as a potential biomarker EC detection. Aberrant in promoter regions tumor suppressor genes can lead to gene silencing progression. We examine recent studies utilizing minimally invasive samples, such urine, cervicovaginal, cervical scrapes, detect early-stage through patterns. Markers RASSF1A, HIST1H4F, GHSR, SST, ZIC1 have demonstrated high accuracy, AUC values up 0.95, effectively distinguishing from non-cancerous conditions. highlights methylation-based testing non-invasive alternative traditional methods, offering earlier detection, better stratification, more personalized treatment plans. These innovations hold promise transforming clinical practice by enabling timely effective management endometrial cancer.

Language: Английский

Minimally Invasive and Emerging Diagnostic Approaches in Endometrial Cancer: Epigenetic Insights and the Promise of DNA Methylation DOI Creative Commons

Floriana Porcaro,

Alessandra Paolucci,

Piercarmine Porcaro

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(22), P. 2575 - 2575

Published: Nov. 15, 2024

Endometrial cancer (EC) is the most common gynecological malignancy, with rising incidence and mortality rates. Key risk factors, including obesity, prolonged estrogen exposure, metabolic disorders, underscore urgent need for non-invasive, early diagnostic tools. This review focuses on role of DNA methylation as a potential biomarker EC detection. Aberrant in promoter regions tumor suppressor genes can lead to gene silencing progression. We examine recent studies utilizing minimally invasive samples, such urine, cervicovaginal, cervical scrapes, detect early-stage through patterns. Markers RASSF1A, HIST1H4F, GHSR, SST, ZIC1 have demonstrated high accuracy, AUC values up 0.95, effectively distinguishing from non-cancerous conditions. highlights methylation-based testing non-invasive alternative traditional methods, offering earlier detection, better stratification, more personalized treatment plans. These innovations hold promise transforming clinical practice by enabling timely effective management endometrial cancer.

Language: Английский

Citations

1